Literature DB >> 10859381

Neither phosphorylation nor the amino-terminal part of rabies virus phosphoprotein is required for its oligomerization.

B Gigant1, F Iseni, Y Gaudin, M Knossow, D Blondel.   

Abstract

Rabies virus (PV strain) phosphoprotein (P) was expressed in bacteria. This recombinant protein binds specifically to the nucleoprotein-RNA complex purified from infected cells. Chemical cross-linking and gel-filtration studies indicated that the P protein forms oligomers. Analytical centrifugation data demonstrated the co-existence of monomeric and oligomeric forms of rabies virus P protein and suggested that there is an equilibrium between these species. As P expressed in bacteria is not phosphorylated, this result indicates that P phosphorylation is not required for its oligomerization. Although an alignment of several rhabdovirus P sequences revealed that the amino-terminal domain of P has a conserved predicted propensity to form helical coiled coils, an amino-terminally truncated form of P protein, lacking the first 52 residues, was also shown to be oligomeric. Therefore, the amino-terminal domain of rabies virus P is not necessary for its oligomerization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10859381     DOI: 10.1099/0022-1317-81-7-1757

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Functional interaction map of lyssavirus phosphoprotein: identification of the minimal transcription domains.

Authors:  Y Jacob; E Real; N Tordo
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  The full-length genome analysis of a street rabies virus strain isolated in Yunnan province of China.

Authors:  Jian Zhang; Hai-lin Zhang; Xiao-yan Tao; Hao Li; Qing Tang; Xiu-yun Jiang; Guo-dong Liang
Journal:  Virol Sin       Date:  2012-06-09       Impact factor: 4.327

3.  Mapping and functional role of the self-association domain of vesicular stomatitis virus phosphoprotein.

Authors:  Mingzhou Chen; Tomoaki Ogino; Amiya K Banerjee
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription.

Authors:  Peggy Möller; Nonia Pariente; Hans-Dieter Klenk; Stephan Becker
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Molecular characterization of the full-length genome of a rabies virus isolate from India.

Authors:  Tirumuru Nagaraja; Shampur Madhusudana; Anita Desai
Journal:  Virus Genes       Date:  2008-03-25       Impact factor: 2.332

6.  Structure of recombinant rabies virus nucleoprotein-RNA complex and identification of the phosphoprotein binding site.

Authors:  G Schoehn; F Iseni; M Mavrakis; D Blondel; R W Ruigrok
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1.

Authors:  Aurore Vidy; Jamila El Bougrini; Mounira K Chelbi-Alix; Danielle Blondel
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

8.  Peptides that mimic the amino-terminal end of the rabies virus phosphoprotein have antiviral activity.

Authors:  Guillaume Castel; Mohamed Chtéoui; Grégory Caignard; Christophe Préhaud; Stéphanie Méhouas; Eléonore Réal; Corinne Jallet; Yves Jacob; Rob W H Ruigrok; Noël Tordo
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

9.  N-terminal phosphorylation of phosphoprotein of vesicular stomatitis virus is required for preventing nucleoprotein from binding to cellular RNAs and for functional template formation.

Authors:  Longyun Chen; Shengwei Zhang; Amiya K Banerjee; Mingzhou Chen
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

10.  The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro.

Authors:  Bin Lu; Chien-Hui Ma; Robert Brazas; Hong Jin
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.